Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
-
Israel reopens key roads as firefighters battle blaze
-
Europe far-right surge masks divisions
-
James will mull NBA future after Lakers playoff exit
-
Ukraine's chief rabbi sings plea to Trump to side with Kyiv
-
Australian mushroom meal victim 'hunched' in pain, court hears
-
Lakers dumped out of playoffs by Wolves, Rockets rout Warriors
-
Booming tourism and climate change threaten Albania's coast
-
US reaching out to China for tariff talks: Beijing state media
-
Tariffs prompt Bank of Japan to lower growth forecasts
-
Kiss faces little time to set Wallabies on path to home World Cup glory
-
Serbian students, unions join forces for anti-corruption protest
-
Slow and easily beaten -- Messi's Miami project risks global embarrassment
-
Fan in hospital after falling to field at Pirates game
-
Nuclear power sparks Australian election battle
-
Tokyo stocks rise as BoJ holds rates steady
-
Bank of Japan holds rates, lowers growth forecasts
-
'Sleeping giants' Bordeaux-Begles awaken before Champions Cup semis
-
Napoli eye Scudetto as Inter hope for post-Barca bounce-back
-
Germany's 'absolutely insane' second tier rivalling Europe's best
-
PSG minds on Arsenal return as French clubs scrap for Champions League places
-
UK WWII veteran remembers joy of war's end, 80 years on
-
Myanmar junta lets post-quake truce expire
-
Rockets romp past Warriors to extend NBA playoff series
-
Messi, Inter Miami CONCACAF Cup dream over as Vancouver advance
-
UN body warns over Trump's deep-sea mining order
-
UK local elections test big two parties
-
US judge says Apple defied order in App Store case
-
Seventeen years later, Brood XIV cicadas emerge in US
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
Formation Metals Announces Appointment of Adrian Smith to Advisory Committee
-
Cerrado Gold Announces Q4 And Annual 2024 Financial Results
-
Australian guard Daniels of Hawks named NBA's most improved
-
Mexico City to host F1 races until 2028
-
Morales vows no surrender in bid to reclaim Bolivian presidency
-
Ukraine, US sign minerals deal, tying Trump to Kyiv
-
Phenomenons like Yamal born every 50 years: Inter's Inzaghi
-
Ukraine, US say minerals deal ready as Kyiv hails sharing
-
Global stocks mostly rise following mixed economic data
-
O'Sullivan says he must play better to win eighth snooker world title after seeing off Si Jiahui
-
Sabalenka eases past Kostyuk into Madrid Open semis
-
Netflix's 'The Eternaut' echoes fight against tyranny: actor Ricardo Darin
-
US economy unexpectedly shrinks, Trump blames Biden
-
Barca fight back against Inter in sensational semi-final draw
-
Meta quarterly profit climbs despite big cloud spending
-
US Supreme Court weighs public funding of religious charter school
-
Climate change made fire conditions twice as likely in South Korea blazes: study
-
Amorim says not even Europa League glory can save Man Utd's season
-
Syria reports Israeli strikes as clashes with Druze spread
Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor.
"This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our 2024 audit puts us in a strong position as we now shift our focus toward the next phase of our corporate growth strategy - including the work required to advance our application to uplist to a more senior stock exchange. We remain committed to transparency, strong governance, and delivering long-term value to our shareholders."
The audited financial statements will be filed on https://www.otcmarkets.com/.
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: | |
OTC Markets: | BINP |
X (formerly Twitter): | @BionoidPharminc |
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
D.Moore--AMWN
